21 U.S.C. § 360bbb–6 — Risk communication

(a) Advisory Committee on Risk Communication (1) In general. The Secretary must create an advisory committee called the "Advisory Committee on Risk Communication." (2) Duties of Committee. The Committee advises the FDA Commissioner on how to effectively explain the risks of products the FDA regulates. (3) Members. The Secretary must make sure the Committee includes risk-communication experts, experts on the specific risks covered in subsection (b), and representatives from patient, consumer, and health professional groups. (4) Permanence of Committee. Federal advisory committees are normally subject to a periodic renewal requirement under section 1013 of title 5. That renewal rule does not apply to this Committee — it is permanent. (b) Partnerships for risk communication (1) In general. The Secretary must team up with professional medical societies, medical schools, academic medical centers, and other stakeholders to build strong, varied systems for telling health care providers about newly emerging drug risks discovered after the drug is already on the market. (2) Partnerships. Those systems must (A) take into account how differently physicians practice, how willing they are to adopt new technology, and their medical specialty, and (B) use the FDA's existing communication channels, including electronic ones.